Global Ankylosing Spondylitis (AS) Market By Drug Type (Non-steroidal Anti-Inflammatory Drugs, TNF Blockers, Immunosuppressive Drugs, Anti-Inflammatory Drugs, Steroids, JAK Inhibitors and Others), Application (Juveniles and Adults), Molecule (Biologics, Bio similar and Small Molecules), Route of Administration (Parenteral, Oral and Others), End User (Hospitals, Clinics, Research Laboratories and Others), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Data Bridge Market Research analyses that the ankylosing spondylitis (AS) market will exhibit a CAGR of around 8.48% for the forecast period of 2021-2028. Increasing prevalence of ankylosing spondylitis (AS) globally, rising expenditure for research and development proficiencies and increasing public and private expenditure for the development of healthcare infrastructure especially in emerging economies are the major factors attributable to the growth of ankylosing spondylitis (AS) market.
Ankylosing spondylitis (AS) is an inflammatory disease that has an adverse impact on the spinal cord. Ankylosing spondylitis (AS) is a kind of arthritis that reduces the flexibility of spine. The inflammation results in excessive lower back pain that gradually shifts to upper spine, neck, and chest.
Upsurge in the in the geriatric population globally susceptible to ankylosing spondylitis (AS) is one of the major factors inducing growth in the ankylosing spondylitis (AS) market value. Rising research and development activities coupled with rise in the number of treatment seeking population will further generate lucrative and remunerative growth opportunities for the ankylosing spondylitis (AS) market. Growing awareness among consumers especially in the developing economies will also act as an important market growth determinant. Increasing number of hospitals and increasing personal disposable income will also propel growth in the market value.
However, loss of patient exclusivity of certain products will derail the market growth rate. High treatment costs will hamper the market growth rate. Low adoption rate of ankylosing spondylitis treatment options will also create hindrances.
This ankylosing spondylitis (AS) market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on ankylosing spondylitis (AS) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Ankylosing Spondylitis (AS) Market Scope and Market Size
The ankylosing spondylitis (AS) market is segmented on the basis of drug type, application, molecule, route of administration and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
- By drug type, the global ankylosing spondylitis (AS) market is segmented into non-steroidal Anti-inflammatory drugs, TNF blockers, immunosuppressive drugs, anti-inflammatory drugs, steroids, JAK inhibitors and others.
- On the basis of application, the ankylosing spondylitis (AS) market is segmented into juveniles and adults.
- On the basis of molecule, the ankylosing spondylitis (AS) market is segmented into biologics, bio similar and small molecules.
- On the basis of route of administration, the ankylosing spondylitis (AS) market is segmented into parenteral, oral and others.
- On the basis of end user, the ankylosing spondylitis (AS) market is segmented into hospitals, clinics, research laboratories and others.
Ankylosing Spondylitis (AS) Market Country Level Analysis
The ankylosing spondylitis (AS) market is analysed and market size insights and trends are provided by country, drug type, application, molecule, route of administration and end user as referenced above.
The countries covered in the ankylosing spondylitis (AS) market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the ankylosing spondylitis (AS) market owing to the high prevalence of ankylosing spondylitis (AS) coupled with favourable reimbursement scenario in the region. Asia-Pacific on the other hand is projected to undergo the highest growth rate during the forecast period owing to the large patient pool and improving healthcare infrastructure.
The country section of the ankylosing spondylitis (AS) market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The ankylosing spondylitis (AS) market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for digital health technologies market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the ankylosing spondylitis (AS) market. The data is available for historic period 2010 to 2019.
Competitive Landscape and Ankylosing Spondylitis (AS) Market Share Analysis
The ankylosing spondylitis (AS) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to ankylosing spondylitis (AS) market.
The major players covered in the ankylosing spondylitis (AS) market report are Janssen Pharmaceuticals, Inc., Sandoz International GmbH , Reliance Life Sciences., Xian Janssen Pharmaceutical Ltd., Trinity Biotech Ireland, Celltrion Inc., F. Hoffmann-La Roche Ltd, Novartis AG, Astrazeneca, Pfizer Inc., Sanofi, Johnson & Johnson Services, Inc., AbbVie Inc., Allergan, Merck & Co., Inc., Amgen Inc., Abbott, Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc. and CELGENE CORPORATION among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.